DDInter1921 DDInter1376
Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V<sub>1</sub> and V<sub>2</sub> cellular receptors.[A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Vasopressin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Vasopressin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Vasopressin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Vasopressin {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin
Vasopressin may lead to a major life threatening interaction when taken with Fingolimod